China’s biotechnology sector is on track for another record year in licensing activity as global pharmaceutical companies intensify their search for innovative drug candidates to offset looming patent expirations and rising research costs. Data from industry tracker Pharmcube shows that out licensing deals
Chinese healthcare companies are accelerating overseas expansion plans as mainland firms increase their global footprint and send more employees abroad. The strategy is focused on serving Chinese expatriate communities in regions such as the Middle East and Southeast Asia, where language familiarity and
WuXi Biologics has projected a sharp increase in full year earnings for 2025, signaling renewed momentum for China’s leading biologics contract development and manufacturing organization. The company expects profit attributable to equity shareholders to rise by 46.3 percent to approximately 4.91 billion yuan,
Chinese authorities have formally charged Leon Wang, the former regional head of AstraZeneca in China, more than a year after he was detained in connection with investigations into the pharmaceutical group’s operations in the country. The development marks a significant step in a
Mainland Chinese investors have stepped up buying of Hong Kong listed pharmaceutical and biotech stocks, riding a renewed wave of overseas licensing agreements that is reshaping how China’s drug developers access global markets. The shift highlights growing confidence in innovative drug makers at
A deadly explosion at a small biotechnology facility in northern China has left eight people dead, drawing renewed attention to industrial safety standards and regulatory enforcement in the country’s manufacturing and life sciences sectors. The blast occurred in the early hours of Saturday
AstraZeneca has unveiled a 15 billion dollar investment plan in China, underscoring renewed commercial momentum between Beijing and London as the UK prime minister visits the country. The British Swedish pharmaceutical group said the investment, running through 2030, will expand medicines manufacturing and
China could become one of the first countries globally to approve a drug entirely designed by artificial intelligence, signalling a major shift in how new medicines are discovered and developed. Pharmaceutical executives say advances in AI and human genetics are accelerating China’s transition
China’s cell therapy sector is drawing renewed investor interest as NewCure Biotech raised more than 200 million yuan, or about $28 million, in a Series B financing round to accelerate development of its TCR T pipeline targeting solid tumors. The round was co
From trial and error to data driven discovery Drug discovery has traditionally been a slow and uncertain process shaped by trial and error. In China, artificial intelligence is changing this dynamic by introducing data driven methods that compress research timelines and improve decision
